Clinical trial · Interventional
Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes
A Phase 3, Prospective, Open-Label, Multicenter Comparison Study of Lymphoseek® and Vital Blue Dye as Lymphoid Tissue Targeting Agents in Patients With Known Melanoma or Breast Cancer Who Are Undergoing Lymph Node Mapping
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Data from this pivotal clinical trial will be used to support a marketing application (i.e., NDA) of Navidea's Lymphoseek for use in anatomical delineation of lymphoid tissue (nodes) in the lymphatic pathway draining the primary site of a tumor. Multicenter, open-label, within-patient comparative study of Lymphoseek and vital blue dye in the detection of excised lymph nodes in patients with known melanoma and breast cancer. All patients will receive a single dose of 50 µg Lymphoseek radiolabeled with 0.5 or 2.0 mCi Tc 99m and vital blue dye.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Melanoma | Melanoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Lymphoseek | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Lymphoseek, Lymphatic mapping, Injection
- interventionNames
- Drug: Lymphoseek
Primary outcomes (1)
- measure
- Concordance of Blue Dye and Lymphoseek
- timeFrame
- Surgery after injections of Lymphoseek and blue dye
- description
- The proportion of lymph nodes detected intraoperatively by blue dye that were also detected by Lymphoseek.
Secondary outcomes (1)
- measure
- Reverse Concordance of Blue Dye and Lymphoseek
- timeFrame
- Surgery after injections of Lymphoseek and blue dye
- description
- The proportion of lymph nodes detected intraoperatively by Lymphoseek that were also detected by blue dye.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. The patient has provided written informed consent with HIPAA authorization. 2. The patient is a candidate for surgical intervention, with lymph node mapping being a part of the surgical plan. 3. The patient is at least 18 years of age at the time of consent. 4. The patient has an ECOG performance status of Grade 0 - 2 (see Appendix A). 5. The patient has a clinical negative node status at the time of study entry (i.e. T0-4, N0, M0, see Appendix D and E). 6. If of childbearing potential, the patient has a negative pregnancy test within 72 hours prior to administration of Lymphoseek, has been surgically sterilized, or has been postmenopausal for at least 1 year. Melanoma Patients 7. The patient has a diagnosis of primary melanoma. Breast Cancer Patients 8. The patient has a diagnosis of primary breast cancer. 9. Patients with pure ductal carcinoma in situ (DCIS) or non-invasive carcinoma if lymph node biopsy is part of the surgical plan. Exclusion Criteria: 1. The patient is pregnant or lactating. 2. The patient has clinical or radiological evidence of metastatic cancer including palpably abnormal or enlarged lymph nodes (i.e., all patients should be any T,N0,M0, see Appendix D and E). 3. The patient has a known hypersensitivity to Lymphazurin. 4. The patient has participated in another investigational drug study within 30 days of scheduled surgery. Melanoma Patients 5. The patient has a tumor with a Breslow depth less than 0.75mm. 6. Patient has had preoperative chemotherapy, immunotherapy, or radiation therapy. 7. Patient has been diagnosed with a prior invasive melanoma that would occur on the same body region or potentially draining to the same nodal basin or patients with truncal or extremity primary melanoma who has had a prior breast cancer potentially draining to the same axillary nodal basin. 8. Patient has undergone node basin surgery of any type or radiation to the nodal basin(s) potentially draining the primary melanoma. 9. Patient has undergone a wide excision for their primary melanoma (\>1 cm in dimension) or complex reconstruction (rotation, free flap, or skin graft of any type). Breast Cancer Patients 10. The patient has bilateral primary breast cancers or multiple tumors within their breast. 11. Patient has had prior surgical procedures such as breast implants, reduction mammoplasty, or axillary surgery. 12. Patient is scheduled for bilateral mastectomy unless for cosmetic reasons and the contraindicated breast will not undergo lymph node mapping. 13. Patient has had preoperative radiation therapy to the affected breast or axilla.
References
Publications (2)
- RESULTWallace AM, Han LK, Povoski SP, Deck K, Schneebaum S, Hall NC, Hoh CK, Limmer KK, Krontiras H, Frazier TG, Cox C, Avisar E, Faries M, King DW, Christman L, Vera DR. Comparative evaluation of [(99m)tc]tilmanocept for sentinel lymph node mapping in breast cancer patients: results of two phase 3 trials. Ann Surg Oncol. 2013 Aug;20(8):2590-9. doi: 10.1245/s10434-013-2887-8. Epub 2013 Mar 17. PMID 23504141
- RESULTSondak VK, King DW, Zager JS, Schneebaum S, Kim J, Leong SP, Faries MB, Averbook BJ, Martinez SR, Puleo CA, Messina JL, Christman L, Wallace AM. Combined analysis of phase III trials evaluating [(9)(9)mTc]tilmanocept and vital blue dye for identification of sentinel lymph nodes in clinically node-negative cutaneous melanoma. Ann Surg Oncol. 2013 Feb;20(2):680-8. doi: 10.1245/s10434-012-2612-z. Epub 2012 Oct 3. PMID 23054107